A Novel Mutation (S54C) of the *PAX8* Gene in a Family with Congenital Hypothyroidism and a High Proportion of Affected Individuals

Panudda Srichomkwun^a Osnat Admoni^c Samuel Refetoff^{a, b} Liat de Vries^{d, e}

^aDepartment of Medicine and ^bDepartment of Pediatrics and the Committee on Genetics, The University of Chicago, Chicago, Ill., USA; ^cPediatric Endocrine Unit, Ha'Emek Medical Center, Afula, ^dInstitute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva, and ^eSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Established Facts

- *PAX8* gene mutations are one of the genetic causes of thyroid dysgenesis.
- To date, 22 different *PAX8* gene mutations have been reported in humans.

Novel Insights

- Identification of a novel single nucleotide substitution (c.162 A>T) in the *PAX8* gene that resulted in the replacement of the normal serine 54 with a cysteine (S54C) in a large family with variable magnitude of hypothyroidism and with a high proportion of affected individuals.

Key Words

Genetic endocrine disorder · Hypothyroidism · Novel mutation · Thyroid hemiagenesis · *PAX8* · Thyroid

Abstract

Background: Congenital hypothyroidism (CH) is a common endocrine disorder in newborns. The cause of CH is thyroid dysgenesis in 80–85% of patients. Paired box gene 8 (*PAX8*) is a thyroid transcription factor that plays an important role in thyroid organogenesis and development. To date, 22 different *PAX8* gene mutations have been reported. **Methods:** Four generations of a Hungarian Jewish family were affected, and in the 3 generations studied, 9 males and 4 females

were affected and 3 first-degree relatives were unaffected. Six were diagnosed at birth [thyroid-stimulating hormone (TSH) level 59–442 mU/l] and 7 at 2–48 years of age (TSH level 6–223 mU/l). One affected patient had thyroid hemiagenesis on ultrasound. **Results:** Direct sequencing of the *PAX8* gene revealed a novel single nucleotide substitution (c.162 A>T) in exon 2 that resulted in the substitution of the normal serine 54 with a cysteine (S54C), which segregated with elevated serum TSH levels. Other mutations of the same amino acid (S54G and S54R) have also been shown to produce functional impairment. **Conclusion:** We report a large family with a novel mutation in the *PAX8* gene presenting with variable phenotype and with a high proportion of affected family members.

© 2016 S. Karger AG, Basel

Introduction

Congenital hypothyroidism (CH; OMIM: 218700) is a common endocrine disorder in newborns with an incidence of 1:4,000 to 1:1,500, depending on the assigned cutoff thyroid-stimulating hormone (TSH) value [1, 2]. In 80–85% of cases, CH is secondary to thyroid dysgenesis, which presents with a thyroid gland that may be absent (athyreosis), hypoplastic (hypoplasia), or located in an unusual position (ectopy). In the remaining 15–20% of cases, CH results from inborn errors of thyroid hormone biosynthesis, secretion, or recycling (dyshormonogenesis) [3]. Thyroid dysgenesis occurs mostly as a sporadic disease; however, a genetic cause has been demonstrated in about 5% of the reported cases. To date, mutations in genes involved in thyroid organogenesis have been identified in the following genes: thyroid transcription factors 1 and 2 (*TTF1* or *NKX2.1* and *TTF2* or *FOXE1*), NK2 homeobox 5 (*NKX2.5*), thyrotropin receptor (*TSHR*), transcription factor GLI similar 3 (*GLIS3*), and the paired box gene 8 (*PAX8*) [4] [*PAX8* OMIM: 167415]. The latter, a paired domain-containing protein belonging to the Pax

family of transcription factors, is expressed in the thyroid gland, kidney, and central nervous system [5]. The *PAX8* gene is located on human chromosome 2q12-q14 and consists of 11 exons encoding a 128-amino-acid protein, which plays an important role in thyroid organogenesis [4]. In the adult thyroid, *PAX8* is an essential regulator of thyroid-specific gene expression such as thyroid peroxidase (*TPO*), thyroglobulin (*TG*), and sodium/iodide symporter (*NIS*) [6]. *PAX8* gene mutations are inherited in an autosomal dominant fashion [4], which contrasts with the recessive inheritance in Pax8 knockout mice [7]. To date, 22 different *PAX8* gene mutations have been reported in humans [4, 8]. Systematic *PAX8* gene mutation screening was performed in 17 cohorts of patients with CH. Mutations occurred with a prevalence of 1.0%, ranging from 0 to 3.4% [8, 9]. The clinical phenotype of individuals with identical *PAX8* gene mutations can be variable, ranging from overt CH with severe thyroid hypoplasia to subclinical CH with a morphologically normal gland. The majority of *PAX8* gene mutations are located within the DNA-binding paired domain and result in a severe reduction in DNA-binding affinity [3].

Fig. 1. Pedigree of the family and results of the thyroid function test before and after treatment. Round and square symbols denote females and males, respectively. Each generation corresponds to a Roman numeral. Arabic numerals above each symbol identify the subjects. Laboratory data are aligned below each symbol. Abnormal values are given in bold. Filled and open symbols denote hypothyroid and euthyroid subjects, respectively. Gray symbols de-

note the presence of a heterozygous *PAX8* gene mutation. The question mark in the symbol of subject I-2 indicates that while she likely carried the *PAX8* gene mutation, this was not confirmed as she was deceased at the time the genetic study was undertaken. FT₄ = Free T₄; NA = not assessed; FT₄I = free T₄ index; L-T4 = levothyroxine.

Patients and Methods

Case History

Four generations of a Jewish family of Hungarian origin were affected. Of the three generations studied, 9 males and 4 females were affected and 3 were unaffected first-degree relatives (fig. 1). Of the 6 miscarriages, 5 occurred in 1 woman (III-8). Clinical features of all family members are shown in table 1. Affected individuals had hypothyroidism of variable severity diagnosed at different ages. None of them had autoantibodies to thyroperoxidase or thyroglobulin. Six (patient IV-3, IV-4, IV-6, IV-9, IV-10, and IV-11) were diagnosed at birth with TSH values ranging from 59 to 442 mU/l. The remaining 7 affected individuals were diagnosed at 2–48 years of age, with serum TSH values from 6 to 223 mU/l. Note that in Israel the screening program for CH is based on the measurement of total T₄ (TT₄) followed by a confirmatory TSH test on samples with T₄ values below the 10th percentile. Thus, it is possible that individuals with T₄ within the normal range (for example IV-7) were missed in the neonatal screening. Of note is a striking variability in the initial clinical presentation within the family. For example, in the first nuclear family, patient IV-3 was identified by neonatal screening while his affected brother (IV-2) had a normal TSH value upon neonatal screening and was found to have subclinical hypothyroidism at the age of 6 years. His father (III-1) was found to have overt hypothyroidism at the age of 48 years when he was admitted to hospital for severe weakness. He also showed Parkinson's and chronic kidney disease of unknown

cause with normal renal ultrasound. Renal function tests (serum urea and creatinine) were normal in all affected individuals. Ultrasound of the kidney in 4 other affected family members (IV-6, IV-7, IV-10, and II-3) was normal. In the second nuclear family, patient IV-4 was found to be hypothyroid following neonatal study, while her mother was diagnosed at the age of 14 years after presenting with delayed puberty. No test results prior to treatment could be found. In the third nuclear family, patient IV-6 was found to be hypothyroid following neonatal screening while his younger brother (IV-7) was diagnosed at the age of 3 years with a very high TSH level. His father (III-5) was found to have high TSH values in adulthood, after presenting with dizziness without hypothyroidism-related manifestations. In the fourth nuclear family, patient IV-9 was found to have CH with thyroid hemiagenesis, while in her brother (IV-11), hypothyroidism was diagnosed at the age of 3 years. He had normal thyroid gland imaging, and his father (III-7) had asymptomatic subclinical hypothyroidism identified only while testing for the present study. Six affected individuals had neurologic and cognitive abnormalities, developmental delay, and/or attention deficit hyperactive disorder.

Thyroid Function Tests

Blood was collected locally and shipped for analysis to the Chicago laboratory. TSH, TT₄ and TT₃ were measured on the Elecsys Automated System (Roche Molecular Biochemicals GmbH and Hitachi, Ltd., Indianapolis, Ind., USA) platform, total reverse T₃ by ZenTech (Liege, Belgium), TG by in-house radioimmunoassay,

Table 1. Clinical and genetic characteristics of the examined family members

Family member	Mutation carrier	Gender	Age, years	Age at diagnosis, years	TSH level at diagnosis ^a , mU/l	Free T ₄ at diagnosis ^b , ng/dl	Thyroid imaging	Current height, cm (SD)	Current L-T4 dose, µg/week	Comorbidity
II-3	yes	M	71	NA	NA	NA	normal position, texture and size ^c	171.5 ^c (–0.8)	700	–
II-4	no	F	69	–	–	–	–	NA	–	–
III-1	yes	M	48	48	223	<0.3	NA	166 ^c (–1.6)	unknown dose	CKD, PD
III-2	no	F	48	–	–	–	–	152 ^c (–1.5)	–	–
III-4	yes	F	44	14	NA	NA	NA	162 ^c (–0.05)	900	–
III-5	yes	M	39	30	19.6	0.86	NA	169.8 ^c (–0.8)	450	–
III-6	no	F	40	–	–	–	–	167.5 ^c (0.65)	–	–
III-7	yes	M	30	30	5.8	–	NA	178 ^c (0.5)	–	–
III-8	no	F	30	–	–	–	–	152 ^c (–1.5)	–	–
IV-1	no	M	24	–	–	–	–	171 ^c (–0.7)	–	–
IV-2	yes	M	17	6	17.9	1.09	NA	167.2 (–1.15)	850	–
IV-3	yes	M	14	NS	59	0.66	NA	147 (–1.96)	900	ADHD IGHD
IV-4	yes	F	11	NS	442	0.53	normal position, normal texture ^c	135.3 (–1.31)	700	DD
IV-5	no	F	9	–	–	–	–	135 (0.097)	–	ADHD
IV-6	yes	M	17	NS	20.9	0.92	hypoechoic, normal position ^c	NA	–	LD
IV-7	yes	M	13	3	172	0.76	normal thyroid scan ^d	154 (–0.55)	1,150	ADHD
IV-8	No	F	12	–	–	–	–	153 (0.41)	–	ADHD
IV-9	yes	F	8	NS	120	0.92	thyroid hemiagenesis ^c	120 (–2.08)	455	–
IV-10	yes	F	7	NS	150	0.60	normal thyroid scan ^d	115 (–1.44)	525	–
IV-11	yes	M	3	NS	64	NA	normal thyroid scan ^d	86 (–1.65)	unknown dose	DD

Abnormal values are given in bold. SD = Standard deviation; L-T4 = levothyroxine; NA = not available; CKD = chronic kidney disease; PD = Parkinson's disease; NS = newborn screening; ADHD = attention deficit hyperactive disorder; IGHD = idiopathic growth hormone deficiency; DD = developmental delay; LD = learning disorder. ^a Normal range of TSH value: adult 0.4–3.6 mU/l, at birth <20 mU/l; ^b normal range of free T₄: adult 0.83–2 ng/dl, at birth 0.93–1.48 mg/dl; ^c ultrasound thyroid; ^d technetium scan; ^e final height.

Fig. 2. **a** Chromatograms showing sequences for normal (WT/WT) and heterozygote (Mut/WT); the square box is covering the region of the mutation. **b** Alignment of the Pax8 amino acid sequence encoded by exon 2 and containing the mutant Ser54 in various species, including mammals, amphibians, and fish. Amino acid differences are given in bold letters.

and antibodies to TG and TPO by the Kronus (Star, Idaho, USA). The free T₄ index was calculated from the TT₄ and the resin T₄ uptake ratio.

DNA Analysis

The clinical and genetic studies were approved by the institutional review boards. After written informed consent was obtained from all participating family members, genomic DNA from peripheral mononuclear blood cells was isolated using the QIAamp DNA Mini Kit (Qiagen) followed by amplification of genomic DNA by polymerase chain reaction and direct sequencing of the *PAX8* gene, exons 0 through exon 11. All polymerase chain reaction samples were sequenced using automated fluorescence-based sequencing (3730XL 96 capillary; Applied Biosystem Carlsbad, Calif., USA). Primer sequences are available upon request.

Results

Direct sequencing of exon 0–11 of the *PAX8* gene revealed a novel single nucleotide substitution in exon 2 of the *PAX8* gene (c.162 A>T) that resulted in the substitution of the normal serine 54 with a cysteine (S54C) (fig. 2a). This S54C mutation cosegregated with a biochemical hypothyroid phenotype in all three generations tested (fig. 1). Evaluation of the new sequence alterations using ‘PolyPhen-2’ indicated that this variant is ‘probably damaging’, with a score of 0.997.

Discussion

We identified a novel mutation in the *PAX8* gene, present in all 13 affected individuals of the family. The thyroid phenotype was considerably variable, with respect to (1) thyroid function (overt to subclinical hypothyroidism), (2) onset of disease (at birth to late adulthood), and (3) thyroid gland anatomy (hemiagenesis to normal). Variable phenotypic expression in *PAX8* mutations has been reported in several families. Patients can be euthyroid or severely hypothyroid, and the thyroid development can range from athyreosis to normal-sized orthotropic gland [4, 10–16]. Possible explanations for interfamilial variability include a polygenic etiology, epigenetic mechanisms that cause stochastic variations of gene expression at multiple loci, variation in the timing of *PAX8* expression in embryonic life, or somatic mutations with a dominant effect in a thyroid development gene [17].

The S54C *Pax8* mutation affects a highly conserved amino acid in the paired domain which lies between the second and the third helical region of the N-terminal homeodomain-like motif (fig. 2b). Other mutations of the same amino acid (S54G and S54R) have also been shown to exhibit functional impairment. Meeus et al. [18] identified an S54G mutation in a French family with CH. In addition, one of the affected siblings displayed unilateral

kidney disease. Functional analysis of the mutant PAX8 demonstrated that it is unable to bind a specific *cis*-acting element of the promoter and has almost lost the ability to control together with TTF1 *TG* gene transcription. Hermanns et al. [19] reported an S54R mutation in 2 members of a Turkish family. In vitro studies showed that the mutant protein had an impaired binding to the *TPO* and *TG* gene promoter-binding sites and exerted a dominant negative effect on the wild-type PAX8. Both reports support a functional impairment of a mutant amino acid at this location.

The *PAX8* gene is expressed in the kidney and plays an important role in its development. Urogenital malformations (horseshoe kidney, undescended testes, hydrocele, ureterocele, and kidney agenesis) associated with *PAX8* gene mutations have been previously reported [18, 20]. One of the affected individuals of this family had chronic kidney disease, but kidney ultrasound showed no abnormal urogenital malformation. Four other affected members of the family were found to have normal kidney ultrasounds. Interestingly, 6 affected members of the family had neurologic or cognitive abnormalities including Parkinsonism, developmental delay, and attention deficit hyperactive disorder. This suggests a possible association between the *PAX8* gene mutation and neurocognitive impairment, which has not been previously reported. The *PAX8* gene is transiently expressed during development in the myelencephalon and in the entire length of the neural tube, but no expression is detected in the brain at later stages or in adults [5]. Its role in these

tissues has not been as well demonstrated as in the kidney and thyroid, and no neurological dysfunction is evidenced in *Pax8* knockout mice [7]. Thus, it is currently not possible to determine whether the neurological manifestations could be attributed to the mutation. In this respect, it should be noted that 2 of the 4 family members with attention deficit hyperactive disorder did not carry the *PAX8* gene mutation (IV-5 and IV-8). Another unusual feature is the high proportion of individuals harboring the mutation (13 of 16) when in autosomal dominant inheritance one would have expected an equal number of affected and unaffected cases.

In conclusion, we report a large family with a novel *PAX8* gene mutation (S54C) causing autosomal dominant CH of variable expressivity and with a high proportion of affected individuals.

Acknowledgements

This work is supported in part by grant R37DK15070 from the National Institutes of Health and the Seymour J. Abrams fund for thyroid research (to S.R.). We thank all family members for their participation in this study. We are grateful to the following colleagues for advice in the course of investigation: Dr. Roy E. Weiss, Dr. Alexandra M. Dumitrescu, and Dr. Theodora Pappa.

Disclosure Statement

The authors declare that they have no conflicts of interest.

References

- 1 Dattani M, Brook CG: Outcomes of neonatal screening for congenital hypothyroidism. *Curr Opin Pediatr* 1996;8:389–395.
- 2 Corbetta C, Weber G, Cortinovis F, Calebiro D, Passoni A, Vigone MC, Beck-Peccoz P, Chiumello G, Persani L: A 7-year experience with low blood TSH cutoff levels for neonatal screening reveals an unsuspected frequency of congenital hypothyroidism (CH). *Clin Endocrinol* 2009;71:739–745.
- 3 Nettore IC, Cacace V, De Fusco C, Colao A, Macchia PE: The molecular causes of thyroid dysgenesis: a systematic review. *J Endocrinol Invest* 2013;36:654–664.
- 4 Pohlenz J, Van Vliet G, Deladoëy J: Developmental abnormalities of the thyroid; in Weiss RE, Refetoff S (eds): *Genetic Diagnosis of Endocrine Disorders*. London, Academic Press, 2016, pp 127–136.
- 5 De Felice M, Di Lauro R: Thyroid development and its disorders: genetics and molecular mechanisms. *Endocr Rev* 2004;25:722–746.
- 6 Marotta P, Amendola E, Scarfo M, De Luca P, Zoppoli P, Amoresano A, De Felice M, Di Lauro R: The paired box transcription factor Pax8 is essential for function and survival of adult thyroid cells. *Mol Cell Endocrinol* 2014;396:26–36.
- 7 Mansouri A, Chowdhury K, Gruss P: Follicular cells of the thyroid gland require PAX8 gene function. *Nat Genet* 1998;19:87–90.
- 8 Fu C, Chen R, Zhang S, Luo S, Wang J, Chen Y, Zheng H, Su J, Hu X, Fan X, Luo J, Yi S, Lai Y, Li C, Xie B, Shen Y, Gu X, Chen S: *Pax8* pathogenic variants in Chinese patients with congenital hypothyroidism. *Clin Chim Acta* 2015;450:322–326.
- 9 Szinnai G: Genetics of normal and abnormal thyroid development in humans. *Best Pract Res Clin Endocrinol Metab* 2014;28:133–150.
- 10 de Sanctis L, Corrias A, Romagnolo D, Di Palma T, Biava A, Borgarello G, Gianino P, Silvestro L, Zannini M, Dianzani I: Familial PAX8 small deletion (c.989_992delacc) associated with extreme phenotype variability. *J Clin Endocrinol Metab* 2004;89:5669–5674.
- 11 Hermanns P, Grasberger H, Refetoff S, Pohlenz J: Mutations in the *NKX2.5* gene and the *PAX8* promoter in a girl with thyroid dysgenesis. *J Clin Endocrinol Metab* 2011;96:E977–E981.

- 12 Narumi S, Araki S, Hori N, Muroya K, Yamamoto Y, Asakura Y, Adachi M, Hasegawa T: Functional characterization of four novel *PAX8* mutations causing congenital hypothyroidism: new evidence for haploinsufficiency as a disease mechanism. *Eur J Endocrinol* 2012;167:625–632.
- 13 Macchia PE, Lapi P, Krude H, Pirro MT, Missero C, Chiovato L, Souabni A, Baserga M, Tassi V, Pinchera A, Fenzi G, Grüters A, Busslinger M, Di Lauro R: *PAX8* mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. *Nat Genet* 1998;19:83–86.
- 14 Ramos HE, Carre A, Chevrier L, Szinnai G, Tron E, Cerqueira TL, Leger J, Cabrol S, Puel O, Queinnec C, De Roux N, Guillot L, Castanet M, Polak M: Extreme phenotypic variability of thyroid dysgenesis in six new cases of congenital hypothyroidism due to *PAX8* gene loss-of-function mutations. *Eur J Endocrinol* 2014;171:499–507.
- 15 Bereket A LX, Turoglu T, Aribal E, Refetoff S: Analysis of the *PAX8* gene in congenital hypothyroidism caused by different forms of thyroid dysgenesis in a father and daughter. *J Pediatr Endocrinol Metab* 2004;17:1021–1029.
- 16 Congdon T, Nguyen LQ, Nogueira CR, Habi-by RL, Medeiros-Neto G, Kopp P: A novel mutation (q40p) in *PAX8* associated with congenital hypothyroidism and thyroid hypoplasia: evidence for phenotypic variability in mother and child. *J Clin Endocrinol Metab* 2001;86:3962–3967.
- 17 Fagman H, Nilsson M: Morphogenetics of early thyroid development. *J Mol Endocrinol* 2011;46:R33–R42.
- 18 Meeus L, Gilbert B, Rydlewski C, Parma J, Roussie AL, Abramowicz M, Vilain C, Christophe D, Costagliola S, Vassart G: Characterization of a novel loss of function mutation of *PAX8* in a familial case of congenital hypothyroidism with in-place, normal-sized thyroid. *J Clin Endocrinol Metab* 2004;89:4285–4291.
- 19 Hermanns P, Shepherd S, Mansor M, Schulga J, Jones J, Donaldson M, Pohlenz J: A new mutation in the promoter region of the *PAX8* gene causes true congenital hypothyroidism with thyroid hypoplasia in a girl with Down's syndrome. *Thyroid* 2014;24:939–944.
- 20 Carvalho A, Hermanns P, Rodrigues AL, Sousa I, Anselmo J, Bikker H, Cabral R, Pereira-Duarte C, Mota-Vieira L, Pohlenz J: A new *PAX8* mutation causing congenital hypothyroidism in three generations of a family is associated with abnormalities in the urogenital tract. *Thyroid* 2013;23:1074–1078.